Evidence map›Paper›PMID 39001716›Full record

Observational studyThe Journal of antimicrobial chemotherapy2024

A microbiological and genomic perspective of globally collected Escherichia coli from adults hospitalized with invasive E. coli disease.

Enya Arconada Nuin, Tuba Vilken, Basil Britto Xavier, Joachim Doua, Brian Morrow, Jeroen Geurtsen, Oscar Go, Bart Spiessens, Michal Sarnecki, Jan Poolman and 7 more

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in The Journal of antimicrobial chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. The possibility of Escherichia coli transmission from pregnant women to the neonates.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Enya Arconada NuinLaboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.ORCID 0000-0002-0053-4075
Tuba VilkenLaboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
Basil Britto XavierLaboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.ORCID 0000-0002-5897-0240
Joachim DouaJanssen Research & Development, Infectious Diseases & Vaccines, Janssen Pharmaceutica, Beerse, Belgium.
Brian MorrowJanssen Research & Development, Raritan, NJ, USA.
Jeroen GeurtsenBacterial Vaccines Discovery & Early Development, Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.
Oscar GoJanssen Research & Development, Raritan, NJ, USA.
Bart SpiessensJanssen Research & Development, Infectious Diseases & Vaccines, Janssen Pharmaceutica, Beerse, Belgium.
Michal SarneckiJanssen Vaccines, Branch of Cilag GmbH International, Bern, Switzerland.
Jan PoolmanBacterial Vaccines Discovery & Early Development, Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.
Marc BontenJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Miquel EkkelenkampDepartment of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands.
Christine LammensLaboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
Herman GoossensLaboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
Youri GlupczynskiLaboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
Sandra Van PuyveldeLaboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.ORCID 0000-0001-8434-5732
COMBACTE-NET Consortium/EXPECT Study Group

Funding

European Federation of Pharmaceutical Industries and AssociationsEuropean Union Seventh Framework Program FP7/2007-2013Innovative Medicines Initiative Joint Undertaking 115523Janssen Research & DevelopmentUMC UtrechtUniversity Medical Center Utrecht
6 · The paper itself

Abstract

objectivesEscherichia coli can cause infections in the urinary tract and in normally sterile body sites leading to invasive E. coli disease (IED), including bacteraemia and sepsis, with older populations at increased risk. We aimed to estimate the theoretical coverage rate by the ExPEC4V and 9V vaccine candidates. In addition, we aimed at better understanding the diversity of E. coli isolates, including their genetic and phenotypic antimicrobial resistance (AMR), sequence types (STs), O-serotypes and the bacterial population structure.

methodsBlood and urine culture E. coli isolates (n = 304) were collected from hospitalized patients ≥60 years (n = 238) with IED during a multicentric, observational study across three continents. All isolates were tested for antimicrobial susceptibility, O-serotyped, whole-genome sequenced and bioinformatically analysed.

resultsA large diversity of STs and of O-serotypes were identified across all centres, with O25b-ST131, O6-ST73 and O1-ST95 being the most prevalent types. A total of 45.4% and 64.7% of all isolates were found to have an O-serotype covered by the ExPEC4V and ExPEC9V vaccine candidates, respectively. The overall frequency of MDR was 37.4% and ST131 was predominant among MDR isolates. Low in-patient genetic variability was observed in cases where multiple isolates were collected from the same patient.

conclusionsOur results highlight the predominance of MDR O25b-ST131 E. coli isolates across diverse geographic areas. These findings provide further baseline data on the theoretical coverage of novel vaccines targeting E. coli associated with IED in older adults and their associated AMR levels.

Indexed as

Escherichia coliEscherichia coli InfectionsWhole Genome SequencingAgedAged, 80 and overAnti-Bacterial AgentsBacteremiaFemaleGenetic VariationGenome, BacterialGenomicsGenotypeGlobal HealthHospitalizationHumansMaleAnti-Bacterial Agents

Identifiers

PMID39001716
PMCPMC11368426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.